Gynecology
Phase I-IIa interim data of ovarian cancer treatment released
Published in Women's Health Weekly, November 20th, 2003
At the time of interim analysis, eight patients being treated at Telcyta (500 mg/m2) and carboplatin (AUC 5 or 6) are evaluable. All patients have platinum refractory or resistant disease. Five of the eight evaluable patients (63%) have objective tumor responses by the RECIST criteria, including one complete response.
The overall disease stabilization rate is 88%. Telcyta in combination with carboplatin has been well-tolerated in...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
More Articles from Women's Health Weekly
- Gynecology
Self-collected vaginal swabs are reliable for bacterial vaginosis screening - Osteoporosis
Raloxifene staunches the risk for new vertebral fractures in osteopenic women - Breast Cancer
Alcohol use boosts risk of hormonally sensitive breast cancers in older women - Domestic Violence
Presentation package helps healthcare providers identify, help battered women - Neuroscience
Accelerated estrogen loss hastens Alzheimer Disease - Urinary Incontinence
New treatment could "revolutionize" management of severe incontinence - More from this issue of Women's Health Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
